Fat loss peptide research has accelerated dramatically in the past decade, driven by discoveries in GH fragment biology, incretin receptor pharmacology, and mitochondrial peptide science. This guide covers the key research compounds studied for lipolysis, metabolic enhancement, and adipose tissue reduction — from the well-characterized GH fragments to cutting-edge AMPK activators and triple receptor agonists now in Phase III trials.
Category 1: GH-Derived Lipolytic Peptides
AOD-9604 — The Selective GH Fragment
AOD-9604 (Advanced Obesity Drug 9604) represents the lipolytic domain of growth hormone — residues 177–191 — isolated from the full GH molecule. The critical research finding: AOD-9604 stimulates fat breakdown with equal potency to full GH, while producing no effect on blood glucose or IGF-1 levels. This selectivity provides a cleaner research model for studying GH’s metabolic (rather than anabolic) effects.
AOD-9604 completed Phase I/IIa clinical trials for obesity with an excellent safety profile. In obese rodent models, it reduces body fat 7–13% vs. controls over 8–12 weeks. The mechanism involves β3-adrenergic receptor activation in adipocytes — a pathway distinct from all other GH secretagogues. An unexpected secondary finding: AOD-9604 shows chondrogenic activity, making it relevant to both metabolic and orthopedic research.
Fragment 176-191 — The Most Potent Lipolytic GH Fragment
Fragment 176-191 (HGH Frag 176-191) is structurally similar to AOD-9604 — both are C-terminal GH fragments — but Fragment 176-191 is reported to be approximately 12.5× more potent than full GH in stimulating lipolysis in isolated fat cell cultures. Like AOD-9604, it avoids IGF-1 stimulation and glucose intolerance. Research has specifically shown preferential activity against abdominal/visceral fat in animal models.
Category 2: AMPK-Activating Metabolic Compounds
AICAR — Endogenous AMPK Activator
AICAR mimics low-energy cell states by generating ZMP, which activates AMPK — the master metabolic switch. Activated AMPK blocks fat synthesis, accelerates fat oxidation, and increases glucose uptake. The landmark Evans lab study demonstrated AICAR increases endurance in sedentary mice by 44%, predominantly through fast-to-slow fiber type conversion and mitochondrial biogenesis. As a metabolic research tool, AICAR is particularly valuable for studying the AMPK pathway in isolation.
5-Amino-1MQ — NNMT Inhibitor
5-Amino-1MQ takes a novel approach: by inhibiting NNMT (Nicotinamide N-Methyltransferase), it increases intracellular NAD+ levels and activates SIRT1, fundamentally altering adipocyte gene expression. Cornell research shows 5-Amino-1MQ reduces obesity in high-fat diet mice without caloric restriction — suggesting genuine metabolic rate changes rather than appetite suppression. Its small molecule nature and oral bioavailability make it practically distinct from peptide-based approaches.
Category 3: Next-Generation Metabolic Peptides
Retatrutide — GIP/GLP-1/Glucagon Triple Agonist
Retatrutide represents the frontier of metabolic peptide research. Its Phase II results showing 24.2% body weight reduction over 48 weeks exceeded any previously reported pharmaceutical outcome for obesity. The triple agonism (GIP-R + GLP-1R + Glucagon-R) creates four simultaneous mechanisms: appetite suppression (GLP-1), improved lipid metabolism (GIP), increased energy expenditure (glucagon), and enhanced insulin secretion. Research with Retatrutide is particularly valuable for studying multi-receptor incretin biology.
MOTS-c — Mitochondrial Exercise Mimetic
MOTS-c is encoded within the mitochondrial genome and acts as a metabolic stress sensor. Research in aged mice shows MOTS-c administration reduces obesity, improves insulin sensitivity, and extends healthspan — effects attributed to its activation of AMPK via the folate cycle metabolite AICAR. The connection between MOTS-c and AICAR metabolism makes them complementary research tools for studying AMPK-mediated metabolic adaptation.
Comparison: Mechanisms of Fat Loss Peptides
| Compound | Primary Mechanism | IGF-1 Effect | Appetite Effect | Clinical Stage |
|---|---|---|---|---|
| AOD-9604 | β3-adrenergic lipolysis | None | None | Phase IIa complete |
| Fragment 176-191 | GH lipolytic domain | None | None | Preclinical |
| AICAR | AMPK activation | None | None | Preclinical |
| 5-Amino-1MQ | NNMT inhibition / NAD+ | None | None | Preclinical |
| Retatrutide | GIP/GLP-1/Glucagon | Moderate ↑ | Strong ↓ | Phase III |
| MOTS-c | AMPK via ZMP/AICAR | None | None | Preclinical |
For Research Use Only (RUO). All products are intended for laboratory research purposes only. Not for human consumption or medical use.